Research programme: ion channel modulators - Asahi Kasei Pharma/RaQualia Pharma
Latest Information Update: 21 Nov 2013
At a glance
- Originator Asahi Kasei Pharma Corp; RaQualia Pharma
- Mechanism of Action Ion channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 19 Nov 2013 Early research in Undefined indication in Japan (unspecified route)